GeneDx Director Buys $2.1M in Company Stock

Keith Meister, a director at the genetic testing firm, increases his stake by nearly 1%.

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

GeneDx Holdings Corp. (NASDAQ:WGS) Director Keith Meister purchased 29,495 shares of GeneDx stock in a transaction on Tuesday, March 3rd. The shares were acquired at an average cost of $70.89 per share, for a total transaction of $2,090,900.55. Following the completion of the transaction, Meister now owns 3,088,124 shares of the company's stock, valued at approximately $218,917,110.36.

Why it matters

Insider buying can be a positive signal for investors, as it suggests company leadership has confidence in the business's prospects. GeneDx is a leading provider of genetic and genomic testing services, an industry that has seen significant growth in recent years.

The details

The transaction increased Meister's stake in GeneDx by 0.96%. Meister has been a director at the company since its founding in 2000. GeneDx stock has traded in a range of $55.17 to $170.87 over the past 52 weeks, closing at $82.00 on Thursday.

  • The transaction took place on Tuesday, March 3rd, 2026.

The players

Keith Meister

A director at GeneDx Holdings Corp. and the founder of Corvex Management, an investment management firm.

GeneDx Holdings Corp.

A clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Insider buying by a long-tenured director suggests confidence in GeneDx's future prospects, even as the stock has traded well off its 52-week high. The genetic testing industry continues to see strong growth, and GeneDx's comprehensive suite of services positions it well to capitalize on this trend.